Endocrine and clinical aspects of inositol in polycystic ovarian syndrome


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Polycystic ovary syndrome (PCOS) is characterized by hormonal changes that are commonly associated with insulin resistance. In this connection, the use of Myo-inositol (MYO) is an effective and promising treatment for PCOS, which demonstrates excellent therapeutic options without any significant side effects. The review summarizes current knowledge of the biological mechanisms of action of MYO and D-chiro-inositol, as well as the results of PCOS therapy.

Full Text

Restricted Access

About the authors

Svetlana O. Dubrovina

Rostov State Medical University

Email: s.dubrovina@gmail.com
MD, professor, the main scientific researcher

Liliya V. Krasilnikova

Medical Center «Centromed»

Email: cool.dalida2014@yandex.ru
gynecologist

References

  1. Orio F., Palomba S. Reproductive endocrinology: New guidelines for the diagnosis and treatment of PCOS. Nat. Rev. Endocrinol. 2014; 10(3): 130-2. https//dx.doi.org/10.1038/nrendo.2013.248.
  2. Genazzani A.D., Santagni S., Ricchieri F., Campedelli A., Rattighieri E., Chierchia E. et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J. Obstet. Gynaecol. Res. 2014; 40(5): 1353-60. https//dx.doi.org/10.1111/jog.12319.
  3. Genazzani A.D., Ricchieri F., Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond.). 2010; 6(4): 577-93. https// dx.doi.org/10.2217/whe.10.43.
  4. Sortino M.A., Salomone S., Carruba M.O., Drago F. Polycystic ovary syndrome: insights into the therapeutic approach with inositols. Front. Pharmacol. 2017; 8: 341. https//dx.doi.org/10.3389/fphar.2017.00341. eCollection 2017.
  5. Громова О.А., Торшин И.Ю., Гришина Т.Р., Громов А.Н., Лиманова О.А. Систематический анализ молекулярно-физиологических эффектов миоинозитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия в акушерстве и гинекологии. 2013; 28: 4-12.
  6. Lazarenko R., Geister J., Bayliss D., Larner J., Li C. D-chiro-inositol glycan stimulates insulin secretion in pancreatic ß cells. Mol. Cell. Endocrinol. 2014; 387(1-2): 1-7. https//dx.doi.org/10.1016/j.mce.2014.02.004.
  7. Formuso C., Stracquadanio M., Ciotta L. Myo-inositol vs. D-chiro inositol in PCOS treatment. Minerva Ginecol. 2015; 67(4): 321-5.
  8. Galazjs N., Galazi M., Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol. Endocrinol. 2011; 27(4): 256-62. https//dx.doi.org/10.3109/09513590.2010.538099.
  9. Pizzo A., Laganà A.S., Barbaro L. Comparison between effects of myo-inositol and d-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol. Endocrinol. 2014; 30(3): 205-8. https//dx.doi.org/10.3109/09 513590.2013.860120.
  10. Artini P.G., Di Berardino O.M., Papini F., Genazzani A.D., Simi G., Ruggiero M., Cela V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol. Endocrinol. 2013; 29(4): 375-9. https//dx.doi.org/10.3109/09513590.2012.743020.
  11. Morgante G., Orvieto R., Di Sabatino A., Musacchio M.C., De Leo V. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil. Steril. 2011; 95(8): 2642-4. https//dx.doi.org/10.1016/j.fertn-stert.2011.01.035.
  12. Raffone E., Rizzo P., Benedetto V. Insulin sensitiser agents alone and in cotreatment with r-FSH for ovulation induction in PCOS women. Gynecol. Endocrinol. 2010; 26(4): 275-80.
  13. Вартанян Э.В., Цатурова К.А., Девятова Е.А., Михайлюкова А. С., Левин В.А., Петухова Н.Л., Маркин А.В., Степцова Е.М. Резервы улучшения качества ооцитов при синдроме поликистозных яичников. Проблемы репродукции. 2017; 23(3): 50-4. https//dx.doi.org/10.17116/repro201723350-54
  14. Громова О.А., Торшин И.Ю., Лиманова О.А. Перспективы использования миоинозитола у женщин с поликистозом яичников и инсулинорезистентностью в программах прегравидарной подготовки к экстракорпоральному оплодотворению. Эффективная фармакотерапия. 2013; 51: 12-23.
  15. Unfer V., Facchinetti F., Orrù B., Giordani B., Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr. Connect. 2017; 6(8): 647-58. https//dx.doi.org/10.1530/EC-17-0243.
  16. Genazzani A.D., Chierchia E., Rattighieri E., Santagni S., Casarosa E., Luisi M., Genazzani A.R. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone(ACTH) stimulation in overweight hyperinsu-linemic patients with PCOS. Gynecol. Endocrinol. 2010; 26(9): 684-9. https// dx.doi.org/10.3109/09513590.2010.500818.
  17. Genazzani A.D., Prati A., Santagni S., Ricchieri F., Chierchia E., Rattighieri E. et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol. Endocrinol. 2012; 28(12): 969-73. https// dx.doi.org/10.3109/09513590.2012.685205.
  18. Ciotta L., Stracquadanio M., Pagano I., Carbonaro A., Palumbo M., Gulino F. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a doubleblind trial. Eur. Rev. Med. Pharmacol. Sci. 2011; 15(5): 509-14.
  19. Unfer V., Carlomagno G., Dante G., Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol. Endocrinol. 2012; 28(7): 509-15. https//dx.doi.org/10.3109/0951359 0.2011.650660.
  20. Regidor P.A., Schindler A.E., Lesoine B., Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig. 2018; 34(2): pii: /j/hmbci.ahead-of-print/hmbci-2017-0067/hmbci-2017-0067.xml. https//dx.doi.org/10.1515/ hmbci-2017-0067.
  21. Lisi F., Carfagna P., Oliva M.M., Rago R., Lisi R., Poverini R. et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod. Biol. Endocrinol. 2012; 10: 52. https//dx.doi.org/10.1186/1477-7827-10-52.
  22. Kamenov Z., Kolarov G., Gateva A., Carlomagno G., Genazzani A.D. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol. Endocrinol. 2015; 31(2): 131-5. https//dx.doi.org/10.3109/09513590.2014.964 640.
  23. Carlomagno G., Unfer V. Inositol safety: clinical evidences. Eur. Rev. Med. Pharmacol. Sci. 2011; 15(8): 931-6.
  24. Werner E.F., Froehlich R.J. The potential role for myoinositol in the prevention of gestational diabetes mellitus. Am. J. Perinatol. 2016; 33(13): 1236-41. https// dx.doi.org/10.1055/s-0036-1584273.
  25. Corrado F., D’Anna R., Di Vieste G., Giordano D., Pintaudi B., Santamaria A., Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet. Med. 2011; 28(8): 972-5. https// dx.doi.org/10.1111/j.1464-5491.2011.03284.x
  26. Krapels I.P., Rooij I.A., Wevers R.A., Zielhuis G.A., Spauwen P.H., Brussel W., Steegers-Theunissen R.P. Myo-inositol, glucose and zinc status as risk factors for non-syndromic cleft lip with or without cleft palate in offspring: a case-control study. BJOG. 2004; 111(7): 661-8.
  27. Wdowiak A. Myoinositol improves embryo development in PCOS patients undergoing ICSI. Int. J. Endocrinol. 2016; 2016: 6273298.
  28. Regidor P.A., Schindler A.E. Myoinositolas a safe and alternative approach in the treatment of infertile PCOS women: A German Observational Study. Int. J. Endocrinol. 2016; 2016: 9537632. https//dx.doi.org/10.1155/2016/9537632.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies